Keytruda

News

Keytruda gets front-line gastric cancer okay in EU

The European Commission has given approval to MSD's Keytruda as a first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

News

Keytruda backed for 'basket' of new cancers via NHS

The UK's cost-effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of cancers based on genetic abnormalities known as microsatellite instab

News

Jemperli cleared for frontline use in endometrial cancer

GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherap

News

Study backs earlier use of Keytruda in cervical cancer

A phase 3 trial of Merck & Co’s checkpoint inhibitor Keytruda could support the expansion of its use in cervical cancer to include newly-diagnosed patients with less s

News

EMA starts review of GSK’s Jemperli in endometrial cancer

GSK has moved a step closer to approval of its cancer immunotherapy Jemperli as a first-line treatment for endometrial cancer in the EU.

News

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

Two late-stage trials combining Merck & Co’s cancer immunotherapy Keytruda with Eisai’s targeted cancer drug Lenvima have generated disappointing results in hard-to-tr

Keytruda gets front-line gastric cancer okay in EU

Keytruda backed for 'basket' of new cancers via NHS

Jemperli cleared for frontline use in endometrial cancer

Study backs earlier use of Keytruda in cervical cancer

EMA starts review of GSK’s Jemperli in endometrial cancer

Phase 3 setbacks mar Eisai, Merck’s cancer alliance

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Keytruda

Editor's Picks